EXTON, Pa., Nov. 9, 2015 /PRNewswire/ — Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company developing Tumor Paint technology. Under the agreement, Morphotek provides to Blaze an exclusive, worldwide, royalty-bearing …